Health AI Central
Share:
Peer-Reviewed Publication
Milbank Q2025;103(S1):319-336.November 1, 2025Journal Article

How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States.

Stephan R Lindner1,2, Jennifer Hall3, Brynna Manibusan1, Jordan Byers3, Kyle Hart1, Andrea Baron4, Dennis McCARTY1,2,5, K John McCONNELL1,2, Deborah J Cohen3
1Center for Health Systems Effectiveness, Oregon Health & Science University.
2OHSU-PSU School of Public Health.
3Oregon Health & Science University.
4Boulder Care.
5School of Medicine, Oregon Health & Science University.
PubMed PMC DOI PDF

Abstract

UNLABELLED: Policy Points States can use substance use disorder waivers to improve their program, but findings regarding the effects of these waivers on opioid use disorder medication treatment have shown mixed results. This study used a mixed-methods design to identify strategies that states undertook as part of their waiver and that may have led to increases in the use of methadone or buprenorph…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.